Table 2.
Demographic and clinical characteristics of the patients, according to age group and SARS-CoV-2 status.
| Characteristics | Overall (N = 39) | <5 Years (N = 25) | ≥5 Years (N = 14) | p-Value | SARS-CoV-2 History Positive (N = 9) |
SARS-CoV-2 History Unknown (N = 18) | SARS-CoV-2 History and Results Negative (N = 12) | p-Value |
|---|---|---|---|---|---|---|---|---|
| n, n/N or Med (% or IQR) | n, n/N or Med (% or IQR) | n, n/N or Med (% or IQR) | n, n/N or Med (% or IQR) | n, n/N or Med (% or IQR) | n, n/N or Med (% or IQR) | |||
| Age [years] | 3.1 (1.4–6.6) | 1.8 (0.85–2.8) | 9.15 (6.4–12.15) | <0.01 * | 10.5 (7–13.4) | 3.3 (1.9–5.4) | 1.2 (0.5–1.6) | <0.01 * |
| Male sex | 29 (74%) | 21 (84%) | 8 (57%) | 0.42 | 4 (44%) | 13 (72%) | 12 (100%) | 0.047 * |
| Any comorbidities | 6/39 (15%) | 3/25 (12%) | 3/14 (21%) | 0.37 | 2/9 (22%) | 3/18 (17%) | 1/12 (8%) | 0.62 |
| Clinical features | ||||||||
| Any dermatologic | 37 (94%) | 20 (80%) | 13 (93%) | 0.39 | 7 (78%) | 17 (94%) | 11 (97%) | 0.39 |
| Rash | 34 (87%) | 22 (88%) | 12 (86%) | 0.60 | 6 (67%) | 17 (94%) | 11 (97%) | 0.11 |
| Hands and feet erythema or swelling | 23 (59%) | 13 (52%) | 10 (71%) | 0.20 | 7 (78%) | 11 (61%) | 5 (42%) | 0.24 |
| Any mucocutaneous | 30 (77%) | 23 (92%) | 10 (71%) | 0.11 | 5 (56%) | 15 (83%) | 10 (83%) | 0.22 |
| Conjunctivitis | 26 (67%) | 17 (68%) | 9 (64%) | 0.54 | 4 (44%) | 13 (72%) | 9 (75%) | 0.27 |
| Mucosal changes | 27 (69%) | 18 (72%) | 9 (64%) | 0.43 | 4 (44%) | 15 (83%) | 8 (67%) | 0.12 |
| Lymphadenopathy | 20 (51%) | 15 (60%) | 5 (36%) | 0.13 | 3 (33%) | 9 (50%) | 8 (67%) | 0.32 |
| Any musculoskeletal | 15 (39%) | 6 (24%) | 9 (64%) | 0.01 * | 5 (56%) | 6 (33%) | 4 (33%) | 0.48 |
| Arthritis (swollen joints) | 8 (21%) | 2 (8%) | 6 (43%) | 0.01 * | 4 (44%) | 3 (17%) | 1 (8%) | 0.11 |
| Arthralgia (without swelling) | 9 (23%) | 2 (8%) | 7 (50%) | <0.01 * | 3 (33%) | 5 (28%) | 1 (8%) | 0.33 |
| Myalgia | 7 (18%) | 3 (12%) | 4 (29%) | 0.19 | 3 (33%) | 1 (6%) | 3 (25%) | 0.15 |
| Any gastrointestinal | 24 (62%) | 13 (52%) | 11 (79%) | 0.09 | 7 (78%) | 10 (56%) | 7 (56%) | 0.52 |
| Nausea or vomiting | 15 (40%) | 6 (24%) | 9 (64%) | 0.02 * | 5 (56%) | 6 (33%) | 4 (33%) | 0.48 |
| Abdominal pain | 16 (42%) | 6 (24%) | 10 (71%) | <0.01 * | 5 (56%) | 7 (39%) | 4 (33%) | 0.22 |
| Diarrhea | 13 (33%) | 8 (32%) | 5 (36%) | 0.54 | 5 (56%) | 4 (22%) | 4 (33%) | 0.22 |
| Any neurologic | 30 (77%) | 21 (84%) | 10 (71%) | 0.29 | 5 (56%) | 13 (72%) | 11 (92%) | 0.16 |
| Neck stiffness | 3 (8%) | 2 (8%) | 1 (7%) | 0.71 | 1 (11%) | 0 | 2 (17%) | 0.61 |
| Somnolence | 17 (44%) | 12 (48%) | 5 (36%) | 0.34 | 4 (44%) | 6 (33%) | 7 (58%) | 0.39 |
| Headache | 6 (15%) | 0 | 6 (43%) | 0.001 * | 5 (56%) | 1 (6%) | 0 | <0.01 * |
| Any respiratory | 16 (41%) | 14 (56%) | 4 (29%) | 0.09 | 4 (44%) | 5 (28%) | 7 (58%) | 0.24 |
| Cough | 6 (15%) | 4 (16%) | 2 (14%) | 0.63 | 2 (22%) | 2 (11%) | 2 (17%) | 0.74 |
| Chest pain | 1 (3%) | 0 | 1 (7%) | - | 1 (11%) | 0 | 0 | - |
| Dyspnea | 4 (10%) | 2 (8%) | 2 (14%) | 0.45 | 2 (22%) | 0 | 2 (17%) | 0.42 |
BCG: Bacillus Calmette–Guérin vaccine; BMI: body mass index; IQR: interquartile range, med: median. We have listed major clinical findings in Table 2. Detailed clinical characteristics are presented in Supplementary Materials (Table S1). * statistically significant (p < 0.05).